BioMark Diagnostics Inc.
BUX
CNSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -2.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.00% | 0.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -2.00% | 0.00% | |||
| SG&A Expenses | 44.30% | -49.77% | |||
| Depreciation & Amortization | 80.31% | -61.36% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.74% | -31.54% | |||
| Operating Income | -15.03% | 31.96% | |||
| Income Before Tax | -78.87% | 47.43% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -78.87% | 47.43% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -78.87% | 47.43% | |||
| EBIT | -15.03% | 31.96% | |||
| EBITDA | -15.21% | 32.24% | |||
| EPS Basic | -71.43% | 46.15% | |||
| Normalized Basic EPS | -66.67% | 43.75% | |||
| EPS Diluted | -71.43% | 46.15% | |||
| Normalized Diluted EPS | -66.67% | 43.75% | |||
| Average Basic Shares Outstanding | 1.21% | 0.00% | |||
| Average Diluted Shares Outstanding | 1.21% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||